Thymus Cancer

Cyfra 21-1 demonstrates potential as a valuable serum biomarker for both the diagnosis and prognosis of thymic tumors. Particular attention should be directed toward the diagnosis, treatment strategy, and postoperative surveillance of patients presenting with elevated Cyfra 21-1 levels.

GSTO1*A140D polymorphism deserves to be further explored as a possible risk factor associated with a worse PFS in thymoma. Specific targets of GSTO1-1 in thymomas need to be determined.

ICIs demonstrated preliminary activity in thymic tumors but were associated with substantial toxicity, especially in thymoma. Biomarker-driven patient selection and vigilant irAE monitoring are needed.

Zin suppresses inflammation, senescence, and apoptosis of oxidized low-density lipoprotein-induced primary human coronary artery endothelial cells in a manner associated with HSP90AB1 silencing. These findings provide a foundation for the further development of Zin-based treatment strategies for CHD.

Integrated profiling of TETs reveals distinct genomic, transcriptomic, and immune features across subtypes of TETs and identifies potentially actionable therapeutic targets that may inform future treatment strategies.

High-dose intravenous methylprednisolone therapy resulted in marked clinical improvement. The absence of intrathecal IgG synthesis raises the possibility that pathogenic antibodies were predominantly derived from the peripheral compartment. These findings underscore the pharmacodynamic limitations of FcRn inhibition, particularly in the setting of thymoma-associated immune dysregulation.

This unique thymic lesion, featuring LFA-like areas admixed with duct-forming lobulated epithelial proliferation, is best classified as a thymic hamartoma. Review of the literature suggests that previously reported LFAs may also represent hamartomatous lesions rather than true neoplasms. Complete surgical resection appears curative. Further case accumulation and molecular studies are needed to elucidate the pathogenesis.

For EGFR-mutant NSCLC, sequential development of tyrosine kinase inhibitors (TKIs) from first- to third-generation agents-culminating in osimertinib-has markedly improved survival. Similarly, successive generations of ALK inhibitors, including alectinib, brigatinib, and lorlatinib, have extended disease control, particularly within the central nervous system. The introduction of antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan for HER2-mutant NSCLC, and emerging TKIs like zongertinib, represent new therapeutic milestones...Beyond lung cancer, our group, in collaboration with Juntendo University ARO (academic research organization) and fifteen institutions in Japan, conducted the MARBLE phase II trial of atezolizumab plus chemotherapy for thymic carcinoma, achieving a 56% objective response rate and 9.6-month median progression-free survival, supporting potential ICI approval in Japan...The DLL3-targeted BiTE tarlatamab significantly improved overall survival to 13.6 months in the phase III DeLLphi-304 trial for relapsed SCLC, with manageable cytokine release syndrome. Collectively, these advances signify a shift toward biologically driven, molecular-targeted or immune-integrated therapy, aiming to transform lung cancer into a chronic, manageable disease in the future, hopefully.

This case illustrates the diagnostic challenges of pediatric T-PLL and demonstrates that a multidisciplinary correlation of clinical, histological, immunophenotypic, and molecular features-together with repeated biopsy and comprehensive immunophenotyping-can be decisive for timely and accurate diagnosis.

Although they share some similarities, s-MG-IM represents a chronic, predominantly thymoma-associated overlap syndrome with classical MG and IM features, whereas ir-MG-IM is typically an aggressive, likely monophasic condition characterized by severe myositis, with frequent ocular and cardiac involvement, and lacking classical MG features. Study limitations include the retrospective design, small sample size, and limited serum availability, warranting confirmation in larger prospective cohorts.

MTAP-deleted thoracic tumors exhibit reproducible clinical and molecular features across populations. Our findings support the rational, globally applicable development of MTAP-targeted synthetic lethal strategies in thoracic malignancies, particularly in combination with molecular targeted agents.